Project

Topics :
Organisms :
Group :
Name of Applicant : Bianca Balbino
Date of application : 03-06-2019
Unit : Antibodies in Therapy and Pathology
Location : Metchnikoff – 4eme etage – room 4006A
Phone : 9146
@ Mail : bbalbino@pasteur.fr
@ PI-Mail : pierre.bruhns@pasteur.fr

---

Project context and summary :

The therapeutic anti-IgE antibody Omalizumab is used for the treatment of severe asthma, and is known to trigger anaphylaxis in some patients. Since Omalizumab is a humanized IgG1, so we hypothesized that Omalizumab could trigger anaphylaxis through the alternative FcgR-mediated pathway. Indeed, we observed that Omalizumab can trigger anaphylaxis in genetically modified mice expressing human FcgRs. We further produced a mutant version of Omalizumab which can still block IgE but cannot bind FcgRs, and demonstrated that this mutant anti-IgE does not induce FcgR-mediated anaphylaxis.

Related team publications :